➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Express Scripts
McKinsey
Johnson and Johnson
Boehringer Ingelheim
Merck

Last Updated: September 18, 2020

DrugPatentWatch Database Preview

Patent: 5,455,240

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,455,240
Title: Modulators of pneumococcal adhesion to cellular targets involving the platelet activating factor receptor, and uses thereof
Abstract:The present invention relates to compositions and methods for preventing pneumococcal infection. In particular, the invention relates to identification of the major reception for Streptococcus pneumoniae on activated human cells, and diagnostic and therapeutic compositions and methods based thereon. In particular, the invention relates to the discovery that platelet activating factor (PAF) receptor is an adhesive ligand for pneumococcal adherence to activated lung epithelial and venous endothelial (i.e., host) cells. Accordingly, the present invention is directed to a method for preventing or treating an infection with Streptococcus pneumoniae by administering an antagonist of platelet activating factor receptor. The invention further relates to recognition that adherence to activated cells also involves a carbohydrate ligand found on such activated cells. Thus, a method for inhibiting pneumococcal adherence may further comprise administering an amount of carbohydrate containing an N-acetyl-D-glucosamine motif. It has been found that resting lung epithelial and venous endothelial cells bear two classes of receptors containing different carbohydrate motifs. Thus, the invention further provides for administering an amount of a second carbohydrate selected from the group consisting of a carbohydrate containing a disaccharide N-acetyl-D-galactosamine .beta.1-4Gal motif, a disaccharide N-acetyl-D-galactosamine .beta.1-3Gal motif, and a mixture thereof. In addition, the invention provides pharmaceutical compositions comprising such agents that inhibit binding of pneumococci to human cells. In a specific example, platelet activating factor receptor antagonists and disaccharides are shown to inhibit binding of pneumococci to activated lung epithelial cells and venous endothelial cells, as well as cells transfected with the platelet activating factor receptor, in vitro.
Inventor(s): Tuomanen; Elaine I. (New York, NY), Cundell; Diana R. (New York, NY), Gerard; Norma P. (Dover, MA)
Assignee: The Rockefeller University (New York, NY) Beth Israel Hospital Association (Boston, MA)
Application Number:08/262,306
Patent Claims:see list of patent claims

Details for Patent 5,455,240

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck Sharp & Dohme Corp. ZOSTAVAX zoster vaccine live INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION 125123 001 2006-05-25   Start Trial The Rockefeller University (New York, NY) Beth Israel Hospital Association (Boston, MA) 2039-09-23 search
Merck Sharp & Dohme Corp. ZOSTAVAX zoster vaccine live INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION 125123 1 2006-05-25   Start Trial The Rockefeller University (New York, NY) Beth Israel Hospital Association (Boston, MA) 2039-09-23 search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Merck
McKesson
Express Scripts
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.